RELMADA THERAPEUTICS, INC.(RLMD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
RLMD Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for RELMADA THERAPEUTICS, INC. (RLMD), a Healthcare sector company. RLMD is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of RLMD by reported 13-F value include Jupiter Topco, BlackRock, Squadron Capital Management, based on the most recent SEC filings. RLMD trades on the Nasdaq exchange and files with the SEC under CIK 1553643. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RLMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RELMADA THERAPEUTICS, INC. directly from SEC EDGAR.
Net Income
Q2 2026
$-12.9M
ROIC
Q2 2026
-29.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+28.3% YoYOperating Income
+29.6% YoYEPS (Diluted)
+45.3% YoYTotal Assets
+105.2% YoYOp. Cash Flow
+11.5% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-57.4M +28.3% | $-80.0M +19.0% | $-98.8M +37.1% | $-157.0M -24.9% | $-125.8M -111.5% | $-59.5M |
| Operating Income | $-59.1M +29.6% | $-83.9M +19.1% | $-103.7M +35.7% | $-161.2M -28.3% | $-125.7M -106.6% | $-60.8M |
| EPS (Diluted) | $-1.45 +45.3% | $-2.65 +19.2% | $-3.28 +38.1% | $-5.30 +26.0% | $-7.16 | — |
| Total Assets | $94.0M +105.2% | $45.8M -53.0% | $97.6M -36.2% | $152.9M -31.5% | $223.3M +89.0% | $118.2M |
| Operating Cash Flow | $-45.8M +11.5% | $-51.8M -0.2% | $-51.7M +50.2% | $-103.8M -13.0% | $-91.9M -230.4% | $-27.8M |
| Free Cash Flow | — | — | — | — | — | $-209.9M |
Get alerted when RLMD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for RELMADA THERAPEUTICS, INC. including:
Top Institutional Holders of RLMD
Jupiter Topco LLC
$77.3M11,164,803 shBlackRock, Inc.
$51.4M7,426,780 shSquadron Capital Management LLC
$50.9M7,350,000 shVR Adviser, LLC
$47.4M6,844,305 shSpruce Street Capital LP
$44.2M6,391,328 shADAGE CAPITAL PARTNERS GP, L.L.C.
$33.0M4,763,158 shVANGUARD CAPITAL MANAGEMENT LLC
$30.9M4,460,210 shJones Hill Capital LP
$25.3M3,655,075 shORBIMED ADVISORS LLC
$25.1M3,631,195 shSTATE STREET CORP
$17.4M2,517,550 sh
| Fund | Value | Shares |
|---|---|---|
| Jupiter Topco LLC | $77.3M | 11,164,803 |
| BlackRock, Inc. | $51.4M | 7,426,780 |
| Squadron Capital Management LLC | $50.9M | 7,350,000 |
| VR Adviser, LLC | $47.4M | 6,844,305 |
| Spruce Street Capital LP | $44.2M | 6,391,328 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $33.0M | 4,763,158 |
| VANGUARD CAPITAL MANAGEMENT LLC | $30.9M | 4,460,210 |
| Jones Hill Capital LP | $25.3M | 3,655,075 |
| ORBIMED ADVISORS LLC | $25.1M | 3,631,195 |
| STATE STREET CORP | $17.4M | 2,517,550 |
More Healthcare Companies
View all Healthcare →Put RLMD on your watchlist
Track score changes the day RELMADA THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RLMD a good stock to buy?
13F Pro's AI-powered analysis of RELMADA THERAPEUTICS, INC. (RLMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RLMD are available on the RLMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RLMD is classified as a small company.
Which hedge funds own RLMD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RLMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RELMADA THERAPEUTICS, INC.'s investment landscape.